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Abstract
Background: Acute coronary syndrome leads to systemic responses, including activation 
of the sympathetic nervous system, inflammation of atherosclerotic lesions, changes in me-
tabolism and gene expressions of remote organs such as the spleen, bone marrow, and liver. 
Clinical trials and experimental studies have demonstrated that therapy with adipose-derived 
regenerative cells (ADRCs) attenuates myocardial ischemia/reperfusion (I/R) injury. The aim 
of this study is to investigate the role of ADRCs in regulating systemic reactions following I/R. 
Methods: Isolated ADRCs were obtained from green fluorescent protein transgenic male mice. 
Flow cytometry revealed that freshly isolated ADRCs expressed stem cell markers CD90 and 
Sca-1, and mesenchymal lineage marker. These cells exhibited multilineage differentiation into 
adipogenic, osteogenic, and chondrogenic lineages. Wild-type mice were subjected to 30 min 
of left ascending coronary ischemia and 24 h reperfusion. Freshly isolated ADRCs (105 cells) 
or vehicle (VEH), were administered intravenously through the tail at the time of reperfusion. 
Results: Compared to VEH, administration of ADRCs significantly reduced circulating 
troponin levels 24 h after I/R. Using quantitative real-time polymerase chain reaction analysis, 
the present study confirms that I/R-induced increase of factor X mRNA expression in the liver and 
was significantly inhibited by ADRCs compared to VEH. Administration of ADRCs significantly 
reduced the I/R-induced increase in serum levels of the proinflammatory cytokines tumor ne-
crosis factor-alpha and interleukin-18 seen in mice receiving VEH. 
Conclusions: These results suggest that administration of ADRCs could have an important role 
in reducing myocardial injury and regulating the hepatic gene expression profile following I/R.  
(Cardiol J 2016; 23, 6: 685–693)
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Introduction
Ischemic heart diseases including acute myo-
cardial infarction (MI), are some of the leading 
causes of morbidity and mortality worldwide [1]. 
Regenerative cell therapies with bone-marrow-
derived mesenchymal stromal cells (MSCs) have 
demonstrated an ability to improve cardiac func-
tion and remodeling in clinical trials [2]. These 
studies, however, did not demonstrate that MSCs 
were able to differentiate into cardiac myocytes, 
or to engraft and replace necrotic myocardium. 
It has been postulated that MSCs act via indirect 
mechanisms other than cell engraftment, such as 
inhibition of inflammation, cytokine production, 
and angiogenesis in promoting cardiac repair [3, 4].
Recent studies have demonstrated that the 
stromal vascular fraction of the adipose tissue 
contains mesenchymal stem cells termed adipose-
derived regenerative cells (ADRCs), not only have 
a capacity for multipotent differentiation, but are 
also able to produce a wide array of growth factors 
and cytokines [5, 6]. Compared to bone marrow, 
subcutaneous adipose tissue represents an effec-
tive source of regenerative therapy because of its 
abundance, surgical accessibility and high content 
of multipotent mesenchymal progenitor cells [7]. 
Acute MI is accompanied by systemic changes in 
inflammation, coagulation, and metabolism, which 
may affect the outcome and prognosis of an acute 
coronary syndrome. Indeed, there are some sys-
temic reactions involving multiple organs, which 
may exacerbate the cardiac events. A previous 
study has shown that hepatic gene expression, 
coagulation factors, and protein C, have levels 
which fluctuate during acute MI and are potentially 
regulated by humoral factors of cardiac origin pro-
voked by myocardial ischemia [8]. Although the 
administration of ADRCs improves cardiac function 
during myocardial ischemia/reperfusion (I/R) injury 
[9], via secreted paracrine factors that attenuate 
inflammation and promote cell survival, the effect 
of ADRC administration on the systemic response 
to myocardial I/R requires further study. 
The aim of the present study is to clarify 
whether the administration of ADRCs affects the 
systemic response following myocardial I/R.
Methods
Ethics statement
All animal protocols were approved by and 
performed in accordance with Guide for the Care 
and Use of Laboratory Animals issued by Kanazawa 
University, which strictly conforms to Guide for 
the Care and Use of Laboratory Animals, published 
by the US National Institutes of Health (NIH, 
Bethesda, MD).
Isolation of adipose-derived  
regenerative cells
The cells making up the adipose stroma were 
isolated adhering to a previously described protocol 
with slight modifications [10]. Briefly, adipose tis-
sue was obtained from the inguinal subcutaneous 
region of 10-week-old non-transgenic (nTg) green 
fluorescent protein transgenic (GFP-Tg) male mice 
(a gift from Professor Okabe, Osaka University, Ja-
pan). After all lymph nodes had been removed, the 
adipose tissue was washed three times with equal 
volumes of phosphate buffered saline (PBS)(–), 
and incubated with Liberase TM Research Grade 
(Roche, Mannheim, Germany). The digested cells 
were centrifuged resuspended in PBS(–) and were 
then filtered with a mesh.
Cell culture and multilineage  
differentiating potential
Cells were cultured under standard cell culture 
conditions with Dullbecco’s modified Eagele’s me-
dium (DMEM)/Nutrient Mixture F-12 1:1 medium 
(Life Technologies-Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% heat-inactivated fetal bo-
vine serum and 1% antibiotic-antimycotic solution 
(Life Technologies). The pluripotency of ADRCs 
was examined using a mouse mesenchymal stem 
cell functional kit (R&D systems, Minneapolis, 
MN, USA) [11]. Differentiation into adipocytes 
was detected by oil red O staining after 14 days of 
incubation in the presence of adipocyte induction 
factors (hydrocortisone, isobuthlmethylxanthine, 
and indomethacin). Differentiation into osteocytes 
was detected by alkaline phosphatase staining 
(Nichirei, Tokyo, Japan), after 14 days of incubation 
in Osteogenic Differentiation Medium. To induce 
chondrogenic differentiation, the cell pellets were 
cultured in 15 mL conical tubes. After 21 days 
of incubation with Chondrogenic Differntiation 
Medium, pellets were harvested, washed in 4% 
paraformaldehyde, and stained with toluidine blue 
(Wako, Tokyo, Japan).
Cell-surface markers
Cell-surface markers on fleshly isolated-
ADRCs were evaluated by flow cytometry using 
the following antibodies [12]: fluorescein isothio-
cyanate (FITC)-conjugated anti-CD45 antibody, 
a marker of bone-marrow-derived cells and anti-
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CD31 antibody, a marker of vascular endothelial 
cells; phycoerythrin (PE)-conjugated CD34 anti-
body, a marker of endothelial progenitor cells; Sca-1, 
CD44 and allophycocyanin (APC)-conjugated 
CD90 antibodies, markers of mesenchymal stem 
cells; and the corresponding isotype controls. All 
antibodies were purchased from BD Pharmingen 
(BD Biosciences, San Jose, CA, USA). Flow cytom-
etry analysis was performed using a FACS Accuri 
C6 (BD Biosciences) cytometer and analyzed with 
FlowJo (Tree Star, Ashland, OR, USA). 
Myocardial ischemia/reperfusion
Male C57BL/6J mice (Charles River Labora-
tories, Yokohama, Japan) were subjected to I/R in 
a sham operation, as described elsewhere [13]. 
A lateral thoracotomy was performed in the anes-
thetized and ventilated mice, and a 7-0 suture was 
looped under the left descending coronary artery 
and used to induce coronary artery occlusion for 
30 min, followed by 24 h of reperfusion. A total of 
105 cells in a volume of 0.2 mL PBS per animal was 
administered intravenously through the tail vein 
after reperfusion. The hearts were removed, and 
the area at risk (AAR) and infarct area (IA) were 
determined using staining with Evans blue and 
2,3,5-triphenyltetrazolium chloride.
Flow cytometry
The distribution of GFP-positive cells in each 
organ was analyzed by flow cytometry [14]. Each 
organ tissue was cut into pieces and treated with 
Liberase at 37°C for 30–60 min with gentle agitation. 
The cells were washed with MACS™ buffer (PBS, 
0.5% BSA, 2 mM EDTA, degassed) twice and filtered 
with a 40-µm cell strainer for single cell suspension. 
Serum troponin I measurement
Blood samples were collected 24 h after I/R. 
Cardiac troponin I (TnI) levels were measured in 
serum using a mouse cardiac TnI ELISA kit (Life 
Diagnostics, Inc, West Chester, PA, USA) in ac-
cordance with manufacturer protocols.
Isolation of mRNA and quantitative  
real-time polymerase chain reaction
Total RNA was isolated using an RNA isolation 
kit (Sigma-Aldrich) in accordance with manufactu-
rer protocols. Total RNA (100 ng) was used to gene-
rate cDNA using the TaqMan Universal Master 
Mix (Applied Biosystems, Foster City, CA, USA), 
in accordance with manufacturer protocols [8]. 
Quantitative real-time polymerase chain reaction 
(qRT-PCR) analysis was performed using the ABI 
Prism 7300 sequence detection system (Applied 
Biosystems). The following primers and TaqMan 
probes (Applied Biosystems) were used: protein C 
(ProC Mm00435966_m1) ,  factor  X (F10 
Mm00484177_m1), CNTF (CNTF Mm00446373_m1), 
and CSF1 (CSF1, Mm 00432686 _m1). Beta actin 
(Actb, Mm02619580_g1) was used as an endoge-
nous control.
Measurement of cytokines and chemokines
Tumor necrosis factor (TNF)-a, interleukin 
(IL)-6, IL-1b, IL-18, macrophage inflammatory 
protein (MIP)-1a, granulocyte-colony-stimulating 
factor (GCSF), regulated on activation normal T cells 
expressed and secreted (RANTES), granulocyte 
macrophage colony-stimulating factor (GMCSF), and 
monocyte chemoattractant protein (MCP)-1 levels in 
serum were monitored using the Bio-Plex Cytokine 
Assay System (Bio-Rad Laboratories, Hercules, CA, 
USA), in accordance with manufacturer protocols [12].
Western blot analysis
Tissue homogenates were prepared using 
RIPA buffer (Upstate). Antibody against factor X 
obtained from Thermo Fisher Scientific. Antibody 
against glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) obtained from Santa-Cruz Bio-
technologies.
Statistics
All values are expressed as mean ± standard 
error of mean. Statistical analyses  performed us-
ing either t-test or one-way ANOVA followed by 
a post hoc Bonferroni-Dunn comparison test. 
A value of p < 0.05 was considered significant. Sta-
tistical analyses were conducted using GraphPad 
Prism (GraphPad Software, La Jolla, CA).
Results
Characterization of ADRCs 
To understand the characteristics of the 
ADRCs, cell surface markers were analyzed. The 
percentages of Sca-1 and CD90, markers of stem 
cells, were 47.0% and 39.2%, respectively, of the 
total nucleated cells (Fig. 1A, B). One-fourth of 
total nucleated cells expressed CD44, the mesen-
chymal linage marker (Fig. 1C) CD45, a marker 
of hematopoietic cells and leukocytes CD31, an 
endothelial cell marker CD34, a myeloid progenitor 
antigen made up 25.1%, 5.2% and 0.8% respec-
tively of the total nucleated cells (Fig. 1D, E, F).
To determine the multilineage differentiation 
of ADRCs their differentiation into adipogenic, 
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osteogenic, and chondrogenic lineages was exam-
ined. After 7 days of incubation in the presence 
of adipogenic differentiation induction factor, fat 
droplets were detected in cell cytoplasm (Fig. 1G). 
These cells were stained with oil red O (Fig. 1H). 
The differentiation of osteocytes was detected by 
alizarin red stain for matrix mineralization (Fig. 
1I) 14 days after incubation in the presence of dif-
ferentiation factors for osteocytes. To determine 
differentiation into chondrocytes, ADRCs were in-
cubated under chondrogenic conditions for 14 days. 
The differentiation of chondrocytes was detected 
by toluidine blue stain (Fig. 1J).
Distribution of administered  
ADRCs in I/R models
To investigate the influence of I/R on the dis-
tribution of intravenously administered ADRCs in 
organs, I/R with sham operated mice were com-
pared. Flow cytometry analysis demonstrated that 
GFP-positive ADRC infusion into I/R mice resulted 
in greater distribution in the heart and liver than 
Figure 1. Characteristics and pluripotency of adipose-derived regenerative cells (ADRCs). ADRCs had stem-cell-
surface markers. Fluorescence-activated cell sorting analysis of ADRCs. The shaded areas represent cells labeled 
with Sca-1 (A), CD90 (B), CD44 (C), CD45 (D), CD31 (E), and CD34 (F). The white areas demonstrate negative controls 
(isotype controls). ADSCs had multipotency of differentiation. The cells had lipid droplets (G) and were positive for 
oil red O stain (H) under the specific stimulation for fat. The cells were positive for alkaline phosphatase under the 
specific stimulation for osteocyte (I). The cells were positive for Alcian Blue stain under the specific stimulation for 
chondrocyte (J). Scale bar, 100 µm for each panel.
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in sham operated mice (Fig. 2). There was no dif-
ference in the distribution of ADRCs in lung tissue 
between I/R mice and sham operated mice.
I/R injury is ameliorated  
by administered ADRCs
To examine the effect of administration of 
ADRCs during I/R injury, 30 min of ischemia and 
subsequent 24 h of reperfusion to I/R mice was 
applied. The mean AAR in the left ventricular area 
was not similar in the ADRCs group and the vehicle 
(VEH) (Fig. 3A, B). The administration of ADRCs 
significantly attenuated I/R-induced increases in 
IA/AAR (Fig. 3C). Furthermore, it was observed 
that administration of ADRCs significantly reduced 
circulating troponin levels in the ADRCs group 
Figure 2. Distribution of adipose-derived regenerative cells (ADRCs) 24 h after intravenous injection. Flow cytome-
tory analysis of green fluorescent protein (GFP)-positive cells in indicated organs after injection of ADRCs from GFP 
transgenic mice; I/R — myocardial ischemia/reperfusion.
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to 3.34 ± 0.31 ng/mL compared with the VEH 
(6.58 ± 1.34 ng/mL) (Fig. 3D).
ADRC treatment alters I/R-induced  
hepatic gene expression
It has been previously shown that myocardial 
I/R affects gene expression profile in the liver, this 
is a remote organ having no changes in hemody-
namic state [8]. Likewise, in this study qRT-PCR 
analysis demonstrated that the mRNA expression 
levels of ProC, factor X, and CNTF in the liver 
were significantly increased in the VEH group 24 h 
after I/R (Fig. 4A–C). I/R-induced upregulation 
of factor X expression in the liver was sig-
nificantly inhibited in the ADRC-treated group 
(Fig. 4B). I/R-induced increases in ProC and 
CNTF mRNA expression levels in the liver were 
not observed in the treatment group (Fig. 4A, C). 
Protein expression of factor X was also increased 
in the VEH and inhibited in the ADRC-treated 
group (Fig. 4E). 
ADRCs treatment reduces I/R-induced  
cytokine concentration in serum
Cytokine levels in the serum were measured 
24 h after I/R. Serum concentrations of TNF-a and 
IL-18 were significantly elevated in VEH group 
24 h after I/R compared with those in sham-operat-
ed mice (Fig. 5A, D). Increases in TNF-a and IL-18 
expression levels were significantly suppressed 
in the ADRCs-treated group when compared with 
those in the VEH group. 
Figure 3. Administration of adipose-derived regenerative cells (ADRCs) inhibits myocardial ischemia/reperfusion 
(I/R) induced myocardial damage. Representative examples of myocardial infarction stained with Evans Blue (EB) 
and triphenyl tetrazolium chloride (TTC) 24 h after reperfusion (A). The area at risk (AAR) was expressed as 
a percentage of the left ventricle (LV) (B). Myocardial infarct area (IA) expressed as a percentage of AAR (C). Troponin I 
levels in vehicle (VEH)- and ADRCs-treated mice at 24 h after reperfusion (D). 
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Discussion
The current study demonstrated an amelio-
rative effect of ADRC therapy on myocardial I/R 
injury in the mouse heart. It has been shown that 
freshly isolated ADRCs, delivered acutely follow-
ing ischemia and reperfusion, were able to protect 
against myocardial damage and regulate systemic 
responses following I/R. While no substantial num-
ber of ADRCs was detected in the infarcted heart, 
infused ADRCs were mainly detected in the lung 
and liver, intravenous systemic administration of 
ADRCs resulted in a reduction of proinflamma-
tory cytokines in serum and affected hepatic gene 
expression profiles following I/R. These results 
suggest that not only engrafted ADRCs, but also 
ADRCs trapped in the lung and liver, exert a pro-
tective effect following I/R injury. 
Clinical trials have shown that cell therapy 
using ADRCs is safe and effective in reducing the 
damage to ischemic myocardium without signifi-
cant engraftment [15]. The intravenous systemic 
administration of stem cells leads to entrapment 
in the lung and liver [16]. Although intravenous 
infusion results in poor engraftment in the heart, 
ADRCs are known to secrete numerous angio-
genic, arteriogenic, chemotactic, and anti-apoptotic 
growth factors [3]. It appears that a paracrine sign-
aling mechanism may be responsible for their fa-
vorable effects [17]. In this study, the distribution 
of freshly isolated ADRCs, delivered just shortly 
following left anterior descending artery occlusion 
and reperfusion, was low in the infarcted heart, but 
the administration of ADRCs did reduce myocar-
dial injury. Similarly, Lee et al. [18] reported that 
the administered cells were distributed not in the 
heart but were detected temporarily in the lung, 
and had anti-inflammatory effects on the remote 
organ mediated by a humoral factor, such as TNF-a- 
-stimulated gene-6. These findings suggest that the 
treatment of acute MI with freshly isolated ADRCs 
is a promising approach.
Several lines of evidence suggest that patients 
with nonalcoholic fatty liver disease have a high 
risk of developing cardiovascular diseases [19, 20], 
and it is reasonable to speculate that the liver is 
involved in a systemic reaction that modifies the 
pathogenesis of acute coronary syndrome. In this 
study, administration of ADRCs reduced myocardial 
I/R-induced upregulation of factor Xa in the liver. 
Inhibition of factor Xa has been shown to reduce 
inflammation in a model of acute myocardial I/R in-
jury [21]. This protective effect has been associated 
with phosphorylation of ERK1/2 and STAT-3 [22, 
23]. These results support the hypothesis that re-
duction of factor Xa expression in the liver may be 
one of the cardiprotective effects caused by ADRC 
administration. The acute-phase response presents 
disturbances of homeostasis due to infection, tis-
sue injury, or immunologic disorders consisting 
of an initial local reaction at the site of injury and 
subsequent systemic reaction. An important part 
of the systemic reaction following cardiac injury 
is the stimulation of protein synthesis in the liver, 
such as protein C and CNTF [8]. In this study, I/R-
-induced upregulation of CNTF and protein C in the 
liver was not observed. This result is dependant 
upon the reduction of myocardial I/R-induced liver 
damage by the administration of ADRCs. Further 
Figure 4. Administration of adipose-derived regenera-
tive cells (ADRCs) affects gene expression in liver at 24 h 
after myocardial ischemia/reperfusion (I/R). Protein C (A), 
coagulation factor X (Factor X) (B), ciliary neurotrophic 
factor (CNTF) (C), colony-stimulating factor-1 (CSF1) (D). 
Protein expression of factor X and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was determined 
by immunoblotting (F).
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Figure 5. Administration of adipose-derived regenerative cells (ADRCs) affects some inflammatory cytokine levels in 
serum at 24 h after myocardial ischemia/reperfusion (I/R). Serum samples were detected by the Bio-Plex Cytokine 
Assay System. Tumor necrosis factor (TNF)-a (A), interleukin (IL)-6 (B), IL-1b (C), IL-18 (D), macrophage inflammatory 
protein (MIP)-1a (E), granulocyte-colony-stimulating factor (GCSF) (F), regulated upon activation of normal T cells 
that express and secrete (RANTES) (G), granulocyte macrophage colony-stimulating factor (GMCSF) (H), monocyte 
chemoattractant protein (MCP)-1 (I); VEH — vehicle.
studies are needed to reveal the role of these pro-
tein expressions in the liver during myocardial I/R.
A growing body of evidence indicates a rela-
tively low rate of stem cell differentiation into 
cardiomyocytes following transplantation, suggest-
ing that the anti-inflammatory effect is one of the 
major mechanisms that mediate cardioprotection 
[24, 25]. Furthermore, in experimental models, 
proinflammatory cytokines, such as TNF-a and 
IL-18 [26], have been shown to significantly in-
crease cardiac rupture and dysfunction through an 
increase in myocyte apoptosis and infarct size. In 
this study, it has been demonstrated that the ex-
pression of TNF-a and IL-18 was induced following 
cardiac I/R. The increase in blood TNF-a levels, 
as a consequence of overproduction of cytokine in 
the border zone of the infarct, which is strongly 
correlated with deleterious effects including left 
ventricular dysfunction [27]. High serum levels of 
IL-18 were also associated with an increased risk 
of developing cardiovascular disease in acute MI 
patients [28]. The pathogenic actions of TNF-a, 
and IL-18 have been implicated in myocardial I/R 
injury and remodeling. Thus, the reduction in the 
levels of these proinflammatory mediators induced 
by ADRC administration may explain the favorable 
effects on I/R injury.
Conclusions
The results of this study show that the ad-
ministration of freshly isolated ADRCs could have 
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a protective effect in reducing myocardial damage 
following I/R, even without engraftment. New in-
sight is offered into these protective mechanisms 
and suggest that they involve changes in systemic 
responses, including hepatic gene expression 
profiles.
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